DNA sequencing pioneer named as BBSRC Innovator of the Year
Prof Shankar Balasubramanian is recognised for the invention of Solexa genome sequencing
Balasubramanian, from the University of Cambridge, is the inventor of Solexa sequencing, an ultrafast method for sequencing DNA. He founded Solexa with colleagues in 1998. Following several rounds of fund raising and the launch of its core product, The Genome Analyser, the company was sold to Illumina for US$600m in 2007. The Solexa product currently has a 50% market share in next generation sequencing and can sequence a human genome for under US$10,000.
Balasubramanian also won the Commercial Innovator of the Year category.
Dr Michael McArthur from the John Innes Centre was awarded £5,000 as the winner of Most Promising Innovator of the Year for his work on using novel antibacterials to combat drug resistant bacterial infections.
Science and Innovation Minister Lord Drayson said: ‘Turning research into innovation is crucial for our future prosperity. Finding practical applications for scientific discoveries is part of the joy of science. Today's winners make science exciting and relevant, with the potential to generate great benefits for our economy and society.’
Balasubramanian accepted the Innovator of the Year Award on behalf of the many people who have made important contributions to the Solexa project, particularly his departmental colleague, Prof David Klenerman, with whom he co-founded Solexa in 1998.
‘None of this would have happened without the support of BBSRC. Their backing was essential for the blue skies research that gave rise to our original inventions. The continued funding of fundamental science by BBSRC will be an essential part of future enterprises and ultimately, wealth creation,’ he said.
The Innovator of the Year Award, now in its second year, recognises and rewards scientists who are ensuring that the UK's bioscience research is translated into outcomes that positively affect quality of life for everyone.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing
Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics
All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing